Admedus (AMEUF) 0.2410 $AMEUF
Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PR Newswire - Thu Mar 24, 1:00AM CDT
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
IMDZ: 8.17 (+0.11), FOMX: 6.59 (+0.19), GNCA: 4.45 (+0.11), NNVC: 1.67 (-0.03)
Biopharmaceutical Market - Forecast (2015 - 2020) - Market Dominated by North America
M2 - Wed Jan 20, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/9xxd67/biopharmaceutical) has announced the addition of the "Biopharmaceutical Market: By Source, By End Users (Hospitals & Others) - Forecast (2015 - 2020)" report to their offering. Biopharmaceuticals are large and complex products isolated from genetically modified living organisms. Recently, biologics or biopharmaceuticals is one of the fastest growing sectors of pharmaceutical industries, owing to its innovative nature, greater safety and efficacy compared to traditional drugs. The market for biopharmaceuticals is classified into three categories based on: - Source - Type of products - Application areas Each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biopharmaceuticals market. The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers. The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biopharmaceuticals market and future opportunities that can propel the market. Companies Mentioned: - Johnson & Johnson Private Limited - Roche Holding AG - Abbott Laboratories - Bristol-Myers Squibb - Novartis International AG - Genentech Inc - UCB - Merck Serono - Amgen - Eli Lilly & Co - Biogen Idec - Merck KGaA - ?lan Corporation - BioMarin Pharmaceutical Inc - AbbVie Inc - Invion Limited - AdAlta Pty Ltd - Admedus Ltd - Biota Pharmaceuticals Inc - Novozymes - Baxter International - APEIRON Biologics AG - Octapharma AG - Valneva SE - Genzyme - Mallinckrodt Pharmaceuticals - TM3 Therapeutics Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Market Forces 5. Market Strategic Analysis 6. Market - By Source 7. Market - By Products 8. Market - By Manufacturing Process 9. Market - By Application 10. Market - By End Users 11. Market - Geographic Analysis 12. Market Entropy 13. Company profiles 14. Appendix For more information visit http://www.researchandmarkets.com/research/9x...maceutical
ABT: 41.89 (+0.53), BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), BOTA: 1.55 (-0.04), AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), BMY: 75.28 (+1.20), JNJ: 122.85 (+0.34), BAX: 46.65 (+0.53), MRK: 59.35 (+0.57), ABBV: 64.16 (+0.73), NVS: 82.13 (+0.33)
Surgical Mesh: Pipeline Review, 2015 - Extensive Coverage of the Surgical Mesh Under Development
M2 - Wed Nov 11, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/2r5jf6/surgical_mesh) has announced the addition of the "Surgical Mesh - Pipeline Review, 2015" report to their offering. Summary Our Medical Devices sector report, Surgical Mesh - Pipeline Review, 2015" provides an overview of Surgical Mesh currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Surgical Mesh pipeline products. Scope - Extensive coverage of the Surgical Mesh under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Surgical Mesh and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 List of Tables and List of Figures 2 Introduction 3 Products under Development 4 Surgical Mesh - Pipeline Products under Development by Companies 5 Surgical Mesh Companies and Product Overview 6 Surgical Mesh- Recent Developments 7 Appendix Companies Mentioned - Acera Surgical, Inc. - Admedus Ltd - Allergan, Inc. - Anika Therapeutics, Inc. - ARISTE Medical - Atrium Medical Corporation - BioLineRx, Ltd. - Boston Scientific Corporation - Cytograft Tissue Engineering, Inc. - DSM Biomedical B.V. - Ethicon, Inc. - Generic Medical Devices, Inc. - Harbor MedTech, Inc. - Hernia Solutions Ltd. - Kerecis ehf - Kinetic Concepts, Inc. - LifeBond Ltd. - Medisse BV - Medlinx Acacia Pte Ltd - Medtronic plc - MicroPort Scientific Corporation - MiMedx Group, Inc - Montana State University - Nanovis Incorporated - PolyNovo Biomaterials Pty Ltd - Proxy Biomedical Limited - Retectix, LLC - Revivicor, Inc. - Samyang Biopharmaceuticals Corporation - Semprus BioSciences - Soft Tissue Regeneration, Inc. - Tepha, Inc. - The Electrospinning Company Ltd - The Johns Hopkins University For more information visit http://www.researchandmarkets.com/research/2r...gical_mesh
BSX: 23.90 (+0.24), AGN: 240.59 (+2.58), MDT: 88.36 (+0.87), ANIK: 53.30 (+0.94), MDXG: 8.25 (+0.14)
Global Human Papillomavirus (HPV) Associated Cancer Pipeline Review, H2 2015 - 32 Companies & 54 Drug Profiles
M2 - Mon Nov 09, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/jsltn6/human) has announced the addition of the "Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Admedus Ltd - Advaxis, Inc. - Antigen Express, Inc. - Bionor Pharma ASA - Cancer Research Technology Limited - Cancer Therapeutics CRC Pty Ltd - Chong Kun Dang Pharmaceutical Corp. - Etubics Corporation - EyeGene, Inc. - Formune S.L. - Genexine, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onconova Therapeutics, Inc. - Oryx GmbH & Co. KG - Prima BioMed Ltd. - Profectus BioSciences, Inc. - Redbiotec AG - Shantha Biotechnics Limited - Sirnaomics, Inc. - Theravectys SA - Transgene SA - Vaccibody AS - Virometix AG - ViroStatics, srl For more information visit http://www.researchandmarkets.com/research/jsltn6/human
ADXS: 8.61 (+0.04), ONTX: 4.70 (-0.29), INO: 9.11 (+0.03), KITE: 48.53 (-3.57), MRK: 59.35 (+0.57), IBIO: 0.68 (unch), NVS: 82.13 (+0.33), KPTI: 7.11 (+0.01)
Global Genital Herpes Pipeline Review 2015 - 19 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqbrzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Admedus Ltd - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - PaxVax - Profectus BioSciences, Inc. - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS - Vaxart, Inc. - Vical Incorporated Drug Profiles - acyclovir - Aspidasept - astodrimer - G-103 - GEN-002 - GEN-003 - genital herpes vaccine [HSV-2] - GV-2207 - HerpeCide-I - herpes simplex virus [serotype 2] vaccine - herpes simplex virus [type 1, 2] vaccine - HSV-529 - pritelivir - SB-105A10 - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/hq...tal_herpes
VICL: 4.49 (+0.08), IMDZ: 8.17 (+0.11), FOMX: 6.59 (+0.19), GNCA: 4.45 (+0.11), NNVC: 1.67 (-0.03)
Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 8.17 (+0.11), CVM: 0.47 (unch), FOMX: 6.59 (+0.19), ADMP: 3.28 (+0.18), GNCA: 4.45 (+0.11), NNVC: 1.67 (-0.03), CMRX: 3.99 (-0.04)
Leading 100 Medical Technology Companies of Asia 2015
M2 - Mon Mar 23, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bxckf/asia_medical) has announced the addition of the "Asia Medical Technology 100 - An Industry Report" report to their offering. One key trend upcoming in this market is the emergence of user-friendly technologies, which reduce the number of hospital visits and help in the close monitoring of a patient's physiological parameters. The emergence of user-friendly technologies permits the frequent evaluation of these parameters without any assistance from a physician. Asia's medical technology industry is projected to experience top line growth at 2-5 times the rate of developed markets. Global medtech industry is expected to hit US$228 billion by 2015, driven largely by an aging population and climbing societal risk factors such as cardiovascular disease and diabetes. Coupled with longer life expectancy and rising affluence in Asia, this presents companies with immense opportunities to expand the reach of their medical products and business networks in the region. Our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of Asian companies in the medical technology industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical technology companies of Asia - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances among Asian medical technology companies - International presence of Asian medical technology companies - R&D activities by Asian medical technology companies Report Includes Companies Engaged in: - Manufacturing research instruments and scientific analytical equipment - Providing software for improving treatments - Providing medical information technology - Manufacturing medical bio-tech products - Providing value-based healthcare services - Manufacturing molecular diagnostic instruments - Manufacturing pacemakers, imaging instruments, dialysis machines and implants, hip and knee replacement medical devices, heart stents, thermal cyclers and mass spectrometers, microarrays and other similar products Companies Mentioned (Partial List) - A&T Corporation (Japan) - Accuray Medical Equipment (India) Private Limited (India) - Admedus Ltd (Australia) - Analytica Limited (Australia) - Angels Health Private Limited (India) - Ashva Technologies Pvt. Ltd. (India) - Asiamedic Limited (Singapore) - Attune Technologies Private Limited (India) - Axsys Health Tech Limited (India) - Azure Healthcare Ltd (Australia) - Beijing Bohui Innovation Tech (China) - Biodenta Corp (Taiwan) - Bionime Corporation (Taiwan) - Bluechiip Limited (Australia) - Brain Resource Ltd (Australia) - Carefusion Development Private Limited (India) - Cogstate Ltd. (Australia) - Compumedics Limited (Australia) - CoWealth Medical Holding Co., Ltd. (China) - CU Medical Systems Inc (Korea (South)) For more information visit http://www.researchandmarkets.com/research/3b...ia_medical
Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PR Newswire - Thu Mar 24, 1:00AM CDT
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
IMDZ: 8.17 (+0.11), FOMX: 6.59 (+0.19), GNCA: 4.45 (+0.11), NNVC: 1.67 (-0.03)
Biopharmaceutical Market - Forecast (2015 - 2020) - Market Dominated by North America
M2 - Wed Jan 20, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/9xxd67/biopharmaceutical) has announced the addition of the "Biopharmaceutical Market: By Source, By End Users (Hospitals & Others) - Forecast (2015 - 2020)" report to their offering. Biopharmaceuticals are large and complex products isolated from genetically modified living organisms. Recently, biologics or biopharmaceuticals is one of the fastest growing sectors of pharmaceutical industries, owing to its innovative nature, greater safety and efficacy compared to traditional drugs. The market for biopharmaceuticals is classified into three categories based on: - Source - Type of products - Application areas Each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biopharmaceuticals market. The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers. The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biopharmaceuticals market and future opportunities that can propel the market. Companies Mentioned: - Johnson & Johnson Private Limited - Roche Holding AG - Abbott Laboratories - Bristol-Myers Squibb - Novartis International AG - Genentech Inc - UCB - Merck Serono - Amgen - Eli Lilly & Co - Biogen Idec - Merck KGaA - ?lan Corporation - BioMarin Pharmaceutical Inc - AbbVie Inc - Invion Limited - AdAlta Pty Ltd - Admedus Ltd - Biota Pharmaceuticals Inc - Novozymes - Baxter International - APEIRON Biologics AG - Octapharma AG - Valneva SE - Genzyme - Mallinckrodt Pharmaceuticals - TM3 Therapeutics Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Market Forces 5. Market Strategic Analysis 6. Market - By Source 7. Market - By Products 8. Market - By Manufacturing Process 9. Market - By Application 10. Market - By End Users 11. Market - Geographic Analysis 12. Market Entropy 13. Company profiles 14. Appendix For more information visit http://www.researchandmarkets.com/research/9x...maceutical
ABT: 41.89 (+0.53), BIIB: 251.30 (+4.03), BMRN: 91.49 (+3.33), BOTA: 1.55 (-0.04), AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), BMY: 75.28 (+1.20), JNJ: 122.85 (+0.34), BAX: 46.65 (+0.53), MRK: 59.35 (+0.57), ABBV: 64.16 (+0.73), NVS: 82.13 (+0.33)
Surgical Mesh: Pipeline Review, 2015 - Extensive Coverage of the Surgical Mesh Under Development
M2 - Wed Nov 11, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/2r5jf6/surgical_mesh) has announced the addition of the "Surgical Mesh - Pipeline Review, 2015" report to their offering. Summary Our Medical Devices sector report, Surgical Mesh - Pipeline Review, 2015" provides an overview of Surgical Mesh currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Surgical Mesh pipeline products. Scope - Extensive coverage of the Surgical Mesh under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Surgical Mesh and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 List of Tables and List of Figures 2 Introduction 3 Products under Development 4 Surgical Mesh - Pipeline Products under Development by Companies 5 Surgical Mesh Companies and Product Overview 6 Surgical Mesh- Recent Developments 7 Appendix Companies Mentioned - Acera Surgical, Inc. - Admedus Ltd - Allergan, Inc. - Anika Therapeutics, Inc. - ARISTE Medical - Atrium Medical Corporation - BioLineRx, Ltd. - Boston Scientific Corporation - Cytograft Tissue Engineering, Inc. - DSM Biomedical B.V. - Ethicon, Inc. - Generic Medical Devices, Inc. - Harbor MedTech, Inc. - Hernia Solutions Ltd. - Kerecis ehf - Kinetic Concepts, Inc. - LifeBond Ltd. - Medisse BV - Medlinx Acacia Pte Ltd - Medtronic plc - MicroPort Scientific Corporation - MiMedx Group, Inc - Montana State University - Nanovis Incorporated - PolyNovo Biomaterials Pty Ltd - Proxy Biomedical Limited - Retectix, LLC - Revivicor, Inc. - Samyang Biopharmaceuticals Corporation - Semprus BioSciences - Soft Tissue Regeneration, Inc. - Tepha, Inc. - The Electrospinning Company Ltd - The Johns Hopkins University For more information visit http://www.researchandmarkets.com/research/2r...gical_mesh
BSX: 23.90 (+0.24), AGN: 240.59 (+2.58), MDT: 88.36 (+0.87), ANIK: 53.30 (+0.94), MDXG: 8.25 (+0.14)
Global Human Papillomavirus (HPV) Associated Cancer Pipeline Review, H2 2015 - 32 Companies & 54 Drug Profiles
M2 - Mon Nov 09, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/jsltn6/human) has announced the addition of the "Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Admedus Ltd - Advaxis, Inc. - Antigen Express, Inc. - Bionor Pharma ASA - Cancer Research Technology Limited - Cancer Therapeutics CRC Pty Ltd - Chong Kun Dang Pharmaceutical Corp. - Etubics Corporation - EyeGene, Inc. - Formune S.L. - Genexine, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onconova Therapeutics, Inc. - Oryx GmbH & Co. KG - Prima BioMed Ltd. - Profectus BioSciences, Inc. - Redbiotec AG - Shantha Biotechnics Limited - Sirnaomics, Inc. - Theravectys SA - Transgene SA - Vaccibody AS - Virometix AG - ViroStatics, srl For more information visit http://www.researchandmarkets.com/research/jsltn6/human
ADXS: 8.61 (+0.04), ONTX: 4.70 (-0.29), INO: 9.11 (+0.03), KITE: 48.53 (-3.57), MRK: 59.35 (+0.57), IBIO: 0.68 (unch), NVS: 82.13 (+0.33), KPTI: 7.11 (+0.01)
Global Genital Herpes Pipeline Review 2015 - 19 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqbrzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Admedus Ltd - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - PaxVax - Profectus BioSciences, Inc. - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS - Vaxart, Inc. - Vical Incorporated Drug Profiles - acyclovir - Aspidasept - astodrimer - G-103 - GEN-002 - GEN-003 - genital herpes vaccine [HSV-2] - GV-2207 - HerpeCide-I - herpes simplex virus [serotype 2] vaccine - herpes simplex virus [type 1, 2] vaccine - HSV-529 - pritelivir - SB-105A10 - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/hq...tal_herpes
VICL: 4.49 (+0.08), IMDZ: 8.17 (+0.11), FOMX: 6.59 (+0.19), GNCA: 4.45 (+0.11), NNVC: 1.67 (-0.03)
Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 8.17 (+0.11), CVM: 0.47 (unch), FOMX: 6.59 (+0.19), ADMP: 3.28 (+0.18), GNCA: 4.45 (+0.11), NNVC: 1.67 (-0.03), CMRX: 3.99 (-0.04)
Leading 100 Medical Technology Companies of Asia 2015
M2 - Mon Mar 23, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bxckf/asia_medical) has announced the addition of the "Asia Medical Technology 100 - An Industry Report" report to their offering. One key trend upcoming in this market is the emergence of user-friendly technologies, which reduce the number of hospital visits and help in the close monitoring of a patient's physiological parameters. The emergence of user-friendly technologies permits the frequent evaluation of these parameters without any assistance from a physician. Asia's medical technology industry is projected to experience top line growth at 2-5 times the rate of developed markets. Global medtech industry is expected to hit US$228 billion by 2015, driven largely by an aging population and climbing societal risk factors such as cardiovascular disease and diabetes. Coupled with longer life expectancy and rising affluence in Asia, this presents companies with immense opportunities to expand the reach of their medical products and business networks in the region. Our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of Asian companies in the medical technology industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical technology companies of Asia - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances among Asian medical technology companies - International presence of Asian medical technology companies - R&D activities by Asian medical technology companies Report Includes Companies Engaged in: - Manufacturing research instruments and scientific analytical equipment - Providing software for improving treatments - Providing medical information technology - Manufacturing medical bio-tech products - Providing value-based healthcare services - Manufacturing molecular diagnostic instruments - Manufacturing pacemakers, imaging instruments, dialysis machines and implants, hip and knee replacement medical devices, heart stents, thermal cyclers and mass spectrometers, microarrays and other similar products Companies Mentioned (Partial List) - A&T Corporation (Japan) - Accuray Medical Equipment (India) Private Limited (India) - Admedus Ltd (Australia) - Analytica Limited (Australia) - Angels Health Private Limited (India) - Ashva Technologies Pvt. Ltd. (India) - Asiamedic Limited (Singapore) - Attune Technologies Private Limited (India) - Axsys Health Tech Limited (India) - Azure Healthcare Ltd (Australia) - Beijing Bohui Innovation Tech (China) - Biodenta Corp (Taiwan) - Bionime Corporation (Taiwan) - Bluechiip Limited (Australia) - Brain Resource Ltd (Australia) - Carefusion Development Private Limited (India) - Cogstate Ltd. (Australia) - Compumedics Limited (Australia) - CoWealth Medical Holding Co., Ltd. (China) - CU Medical Systems Inc (Korea (South)) For more information visit http://www.researchandmarkets.com/research/3b...ia_medical
